NCT04118114View on ClinicalTrials.gov

Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 3, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Gastric CancerHepatocellular CarcinomaAdvanced Solid Tumor
Interventions
DRUG

PRL3-zumab

IV administration every 2 weeks

Trial Locations (1)

169690

RECRUITING

National Cancer Center Singapore, Singapore

All Listed Sponsors
collaborator

INTRA-IMMUSG PRIVATE LIMITED

UNKNOWN

lead

National Cancer Centre, Singapore

OTHER

NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter